Anthony DiGiandomenico
Director/Board Member at ENDRA LIFE SCIENCES INC.
Net worth: 13 M $ as of 2024-03-30
Profile
Mr. Anthony DiGiandomenico is a Director & Chief-Transactions at MDB Capital Holdings LLC, an Independent Director at ENDRA Life Sciences, Inc. and a Managing Director at National Association of Securities Dealers, Inc. He is on the Board of Directors at MDB Capital Holdings LLC, Invizyne Technologies, Inc., ENDRA Life Sciences, Inc., Pier Acquisition I, Inc. and Pier Acquisition II, Inc. Mr. DiGiandomenico was previously employed as an Independent Director by Provention Bio, Inc., a Co-Founder by Public Ventures LLC, and a President & Chief Executive Officer by Digian Co. He also served on the board at Cue Biopharma, Inc., True Drinks Holdings, Inc. and Orion Acquisition Corp.
II.
He received his undergraduate degree from The University of Colorado and an MBA from Haas School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MDB CAPITAL HOLDINGS LLC
24.90% | 2024-03-28 | 1,245,000 ( 24.90% ) | 13 M $ | 2024-03-30 |
| 2024-03-28 | 26,645 ( 0.62% ) | 273 111 $ | 2024-03-30 | |
ENDRA LIFE SCIENCES INC.
0.93% | 2024-03-23 | 102,434 ( 0.93% ) | 59 412 $ | 2024-03-30 |
Anthony DiGiandomenico active positions
| Companies | Position | Start |
|---|---|---|
| ENDRA LIFE SCIENCES INC. | Director/Board Member | 2013-06-30 |
| MDB CAPITAL HOLDINGS, LLC | Director/Board Member | 2021-08-09 |
Pier Acquisition I, Inc.
 Pier Acquisition I, Inc. Financial ConglomeratesFinance Pier Acquisition I, Inc. operates as a blank check company. The company was founded on August 14, 2008 and is headquartered in Calabasas, CA. | Director/Board Member | 2009-11-15 |
Pier Acquisition II, Inc.
 Pier Acquisition II, Inc. Financial ConglomeratesFinance Pier Acquisition II, Inc. was incorporated in the State of Delaware on August 14, 2008. Since inception, the Company has been engaged in organizational efforts and obtaining initial financing. The Company was formed as a vehicle to pursue a business combination and has made no efforts to identify a possible business combination. The Company is considered to be a 'blank check' company. The U.S. Securities and Exchange Commission (the 'SEC') defines as a development stage company. | Director/Board Member | 2009-11-15 |
National Association of Securities Dealers, Inc.
 National Association of Securities Dealers, Inc. Investment Banks/BrokersFinance National Association of Securities Dealers, Inc. provides financial regulatory services. The non-profit company is based in Washington and has subsidiaries in the United States. The American company was founded by Richard B. Jennings, Vince Means. | Corporate Officer/Principal | 2011-07-24 |
Invizyne Technologies, Inc.
 Invizyne Technologies, Inc. Chemicals: SpecialtyProcess Industries Invizyne Technologies, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV. | Director/Board Member | 2019-03-31 |
Former positions of Anthony DiGiandomenico
| Companies | Position | End |
|---|---|---|
| PROVENTION BIO, INC. | Director/Board Member | 2020-05-18 |
| CUE BIOPHARMA, INC. | Director/Board Member | 2019-10-02 |
| CHARLIE'S HOLDINGS, INC. | Director/Board Member | 2012-10-14 |
| ░░░░░ ░░░░░░░░░░░ ░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ | - |
Training of Anthony DiGiandomenico
| The University of Colorado | Undergraduate Degree |
| Haas School of Business | Masters Business Admin |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| CHARLIE'S HOLDINGS, INC. | Producer Manufacturing |
| ENDRA LIFE SCIENCES INC. | Health Technology |
| CUE BIOPHARMA, INC. | Health Technology |
| Private companies | 9 |
|---|---|
| Orion Acquisition Corp. II | Finance |
Public Ventures LLC
 Public Ventures LLC Investment Banks/BrokersFinance Public Ventures LLC is a registered broker-dealer headquartered in Dallas, Texas. The firm was founded by Christopher Marlett and Anthony DiGiandomenico in 1997. They are a wholly-owned subsidiary of MDB Capital Holdings LLC. Public Ventures offers Go-to-Market Strategy, Market Assessments, Revenue Generation and Product Strategy for technology companies that targets the Public Sector. | Finance |
Pier Acquisition I, Inc.
Pier Acquisition I, Inc. Financial ConglomeratesFinance Pier Acquisition I, Inc. operates as a blank check company. The company was founded on August 14, 2008 and is headquartered in Calabasas, CA. | Finance |
Pier Acquisition II, Inc.
Pier Acquisition II, Inc. Financial ConglomeratesFinance Pier Acquisition II, Inc. was incorporated in the State of Delaware on August 14, 2008. Since inception, the Company has been engaged in organizational efforts and obtaining initial financing. The Company was formed as a vehicle to pursue a business combination and has made no efforts to identify a possible business combination. The Company is considered to be a 'blank check' company. The U.S. Securities and Exchange Commission (the 'SEC') defines as a development stage company. | Finance |
National Association of Securities Dealers, Inc.
National Association of Securities Dealers, Inc. Investment Banks/BrokersFinance National Association of Securities Dealers, Inc. provides financial regulatory services. The non-profit company is based in Washington and has subsidiaries in the United States. The American company was founded by Richard B. Jennings, Vince Means. | Finance |
| Digian Co. | |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
| MDB Capital Holdings LLC | |
Invizyne Technologies, Inc.
Invizyne Technologies, Inc. Chemicals: SpecialtyProcess Industries Invizyne Technologies, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV. | Process Industries |
- Stock Market
- Insiders
- Anthony DiGiandomenico
